Cargando…

The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma

BACKGROUND: The clinicopathological and survival profiles across primary sites in acral melanoma (AM) are still controversial and unclear. METHODS: This is a multi-center retrospective study. Clinicopathological data of AM patients diagnosed between 1 January 2000 and 31 December 2017 from 6 large t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Xiaoting, Wu, Di, Li, Hang, Zhang, Rui, Chen, Yu, Yao, Hong, Chi, Zhihong, Sheng, Xinan, Cui, Chuanliang, Bai, Xue, Qi, Zhonghui, Li, Ke, Lan, Shijie, Chen, Lizhu, Guo, Rui, Yao, Xinyu, Mao, Lili, Lian, Bin, Kong, Yan, Dai, Jie, Tang, Bixia, Yan, Xieqiao, Wang, Xuan, Li, Siming, Zhou, Li, Balch, Charles M., Si, Lu, Guo, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410855/
https://www.ncbi.nlm.nih.gov/pubmed/32253677
http://dx.doi.org/10.1245/s10434-020-08418-5
_version_ 1783568266310975488
author Wei, Xiaoting
Wu, Di
Li, Hang
Zhang, Rui
Chen, Yu
Yao, Hong
Chi, Zhihong
Sheng, Xinan
Cui, Chuanliang
Bai, Xue
Qi, Zhonghui
Li, Ke
Lan, Shijie
Chen, Lizhu
Guo, Rui
Yao, Xinyu
Mao, Lili
Lian, Bin
Kong, Yan
Dai, Jie
Tang, Bixia
Yan, Xieqiao
Wang, Xuan
Li, Siming
Zhou, Li
Balch, Charles M.
Si, Lu
Guo, Jun
author_facet Wei, Xiaoting
Wu, Di
Li, Hang
Zhang, Rui
Chen, Yu
Yao, Hong
Chi, Zhihong
Sheng, Xinan
Cui, Chuanliang
Bai, Xue
Qi, Zhonghui
Li, Ke
Lan, Shijie
Chen, Lizhu
Guo, Rui
Yao, Xinyu
Mao, Lili
Lian, Bin
Kong, Yan
Dai, Jie
Tang, Bixia
Yan, Xieqiao
Wang, Xuan
Li, Siming
Zhou, Li
Balch, Charles M.
Si, Lu
Guo, Jun
author_sort Wei, Xiaoting
collection PubMed
description BACKGROUND: The clinicopathological and survival profiles across primary sites in acral melanoma (AM) are still controversial and unclear. METHODS: This is a multi-center retrospective study. Clinicopathological data of AM patients diagnosed between 1 January 2000 and 31 December 2017 from 6 large tertiary hospitals in China were extracted. Chi square tests were used to compare basic characteristics between primary sites of sole, palm and nail bed. Melanoma-specific survival (MSS) differences based on primary sites were compared by log-rank tests and multivariate Cox regressions were used to identify prognostic factors for MSS. RESULTS: In total, 1157 AM patients were included. The sole group had a more advanced initial stage, deeper Breslow thickness, higher recurrence rate and distant metastases risk (all P < 0.05). The proportion of age < 65 years and ulceration were statistically lower in nail bed and palm groups, respectively. A total of 294 patients underwent sentinel lymph node biopsy and rates of positive SLN status had no statistical difference across primary sites. Among 701 patients with genetic profiles, the mutational frequency of BRAF, C-KIT, and PDGFRA were similar except for NRAS (higher in sole group, P = 0.0102). The median MSS of sole, nail bed and palm patients were 65.0 months, 112.0 months, and not reached, respectively (log-rank P = 0.0053). In multivariate analyses, primary site, initial stage, ulceration and recurrence were the prognostic factors for MSS in overall population, but the statistical significance varied over primary sites. CONCLUSIONS: Substantial clinicopathological and survival heterogeneities exist across different primary sites in the AM population. Sole melanoma has worse prognosis compared with palm and nail bed subtypes.
format Online
Article
Text
id pubmed-7410855
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-74108552020-08-17 The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma Wei, Xiaoting Wu, Di Li, Hang Zhang, Rui Chen, Yu Yao, Hong Chi, Zhihong Sheng, Xinan Cui, Chuanliang Bai, Xue Qi, Zhonghui Li, Ke Lan, Shijie Chen, Lizhu Guo, Rui Yao, Xinyu Mao, Lili Lian, Bin Kong, Yan Dai, Jie Tang, Bixia Yan, Xieqiao Wang, Xuan Li, Siming Zhou, Li Balch, Charles M. Si, Lu Guo, Jun Ann Surg Oncol Melanoma BACKGROUND: The clinicopathological and survival profiles across primary sites in acral melanoma (AM) are still controversial and unclear. METHODS: This is a multi-center retrospective study. Clinicopathological data of AM patients diagnosed between 1 January 2000 and 31 December 2017 from 6 large tertiary hospitals in China were extracted. Chi square tests were used to compare basic characteristics between primary sites of sole, palm and nail bed. Melanoma-specific survival (MSS) differences based on primary sites were compared by log-rank tests and multivariate Cox regressions were used to identify prognostic factors for MSS. RESULTS: In total, 1157 AM patients were included. The sole group had a more advanced initial stage, deeper Breslow thickness, higher recurrence rate and distant metastases risk (all P < 0.05). The proportion of age < 65 years and ulceration were statistically lower in nail bed and palm groups, respectively. A total of 294 patients underwent sentinel lymph node biopsy and rates of positive SLN status had no statistical difference across primary sites. Among 701 patients with genetic profiles, the mutational frequency of BRAF, C-KIT, and PDGFRA were similar except for NRAS (higher in sole group, P = 0.0102). The median MSS of sole, nail bed and palm patients were 65.0 months, 112.0 months, and not reached, respectively (log-rank P = 0.0053). In multivariate analyses, primary site, initial stage, ulceration and recurrence were the prognostic factors for MSS in overall population, but the statistical significance varied over primary sites. CONCLUSIONS: Substantial clinicopathological and survival heterogeneities exist across different primary sites in the AM population. Sole melanoma has worse prognosis compared with palm and nail bed subtypes. Springer International Publishing 2020-04-06 2020 /pmc/articles/PMC7410855/ /pubmed/32253677 http://dx.doi.org/10.1245/s10434-020-08418-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Melanoma
Wei, Xiaoting
Wu, Di
Li, Hang
Zhang, Rui
Chen, Yu
Yao, Hong
Chi, Zhihong
Sheng, Xinan
Cui, Chuanliang
Bai, Xue
Qi, Zhonghui
Li, Ke
Lan, Shijie
Chen, Lizhu
Guo, Rui
Yao, Xinyu
Mao, Lili
Lian, Bin
Kong, Yan
Dai, Jie
Tang, Bixia
Yan, Xieqiao
Wang, Xuan
Li, Siming
Zhou, Li
Balch, Charles M.
Si, Lu
Guo, Jun
The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
title The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
title_full The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
title_fullStr The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
title_full_unstemmed The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
title_short The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
title_sort clinicopathological and survival profiles comparison across primary sites in acral melanoma
topic Melanoma
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410855/
https://www.ncbi.nlm.nih.gov/pubmed/32253677
http://dx.doi.org/10.1245/s10434-020-08418-5
work_keys_str_mv AT weixiaoting theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT wudi theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT lihang theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT zhangrui theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT chenyu theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT yaohong theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT chizhihong theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT shengxinan theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT cuichuanliang theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT baixue theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT qizhonghui theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT like theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT lanshijie theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT chenlizhu theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT guorui theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT yaoxinyu theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT maolili theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT lianbin theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT kongyan theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT daijie theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT tangbixia theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT yanxieqiao theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT wangxuan theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT lisiming theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT zhouli theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT balchcharlesm theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT silu theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT guojun theclinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT weixiaoting clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT wudi clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT lihang clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT zhangrui clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT chenyu clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT yaohong clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT chizhihong clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT shengxinan clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT cuichuanliang clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT baixue clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT qizhonghui clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT like clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT lanshijie clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT chenlizhu clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT guorui clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT yaoxinyu clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT maolili clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT lianbin clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT kongyan clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT daijie clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT tangbixia clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT yanxieqiao clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT wangxuan clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT lisiming clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT zhouli clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT balchcharlesm clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT silu clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma
AT guojun clinicopathologicalandsurvivalprofilescomparisonacrossprimarysitesinacralmelanoma